|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Yale University |
|---|---|
| Information provided by: | Yale University |
| ClinicalTrials.gov Identifier: | NCT00611741 |
Purpose
This study is designed to test the hypothesis that plasma osmolality is linked with cortical glutamate concentrations in the brain. It also investigates whether the glutamate response in schizophrenia is enhanced compared to healthy controls.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia |
Drug: furosemide, Na supplements |
Phase I Phase II |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | The Role of Cortical Glutamate and GABA in Brains Osmotic Regulation: A Pilot Study in Healthy Volunteers and in Patients With Schizophrenia |
| Estimated Enrollment: | 30 |
| Study Start Date: | March 2007 |
| Estimated Study Completion Date: | March 2012 |
| Estimated Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 21 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria for healthy controls
Exclusion criteria for healthy controls
Inclusion criteria for patients with schizophrenia
Exclusion criteria for patients with schizophrenia
Contacts and Locations| Contact: Sara Thaxton, BS | 203 932 5711 ext 5326 | sara.thaxton@yale.edu |
| United States, Connecticut | |
| 34 Park Street, CMHC | Recruiting |
| New Haven, Connecticut, United States, 06519 | |
| Principal Investigator: | Handan Gunduz-Bruce, M.D. | Yale School of Medicine |
More Information
| Responsible Party: | Handan Gunduz-Bruce, MD, Yale University |
| ClinicalTrials.gov Identifier: | NCT00611741 History of Changes |
| Other Study ID Numbers: | 0612002149 |
| Study First Received: | January 29, 2008 |
| Last Updated: | February 8, 2008 |
| Health Authority: | United States: Institutional Review Board |
|
MRS, glutamate, osmolality |
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Furosemide Sodium Potassium Chloride Symporter Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Diuretics Natriuretic Agents Physiological Effects of Drugs Cardiovascular Agents Therapeutic Uses |